이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome (IGNITION)

2026년 11월 9일 업데이트: Medisch Spectrum Twente

Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.

Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form.

Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers.

Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice.

Participants will receive:

  1. Standard treatment at the discretion of the cardiologist, or
  2. Genotype-guided treatment (based on the presence of a LOF allele)

Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started.

Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.

연구 개요

상세 설명

Rationale Patients diagnosed with acute coronary syndrome (ACS) require dual antiplatelet therapy (DAPT) for 12 months. This typically includes aspirin and a P2Y12 inhibitor. Irrespective of the treatment strategy (i.e., invasive or conservative), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.

Although ischemic complications usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. Yet, in 30% of the (white) European patients are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate metabolization of clopidogrel.

Despite knowledge of these loss of function mutations, current ACS guidelines do not provide specific recommendations on individualized, genotype-based treatment with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as the conucted trials were underpowered due to sample size calculations based on ischemic endpoints, and the exclusion of ACS patients with high-risk features.

Objective

This randomized clinical trial aims to investigate whether individualized genotype-guided DAPT is non-inferior at 18 months follow-up to standard clinical practice of DAPT in all-comer patients with ACS with regard to:

  • the primary endpoint of Ischemic Endpoint, a composite of cardiovascular death, myocardial infarction, or ischemic stroke, and
  • the co-primary endpoint of Net Adverse Cardiovascular Events (NACE), a composite of major bleeding, cardiovascular death, myocardial infarction, or any stroke.

Trial design This is a randomized, investigator-initiated, multicentre trial with 1:1 randomization of all-comer ACS patients for genotype-guided antiplatelet therapy, stratified for the presence of diabetes mellitus, sex and PCI.

Trial population All patients of 18 years or older with ACS, irrespective of the treatment strategy. If patients did not undergo a coronary angiography, there must be a history of coronary artery disease, proven myocardial defect by cardiac imaging that matches with previous MI, proven myocardial ischemia, or a known coronary obstruction ≥30% as previously visualized.

Interventions

If no major events (defined by NACE) occur during the first 30 days, patients will be randomly assigned (1:1) to:

  1. Standard treatment at the discretion of the cardiologist, or
  2. Genotype-guided treatment (based on CYP2C19 loss of function alleles) Patients included in the genotype-guided group who do not carry a LOF allele will be classified as normal or ultrafast metabolizers, and will de-escalate after 30 days from standard therapy (with ticagrelor or prasugrel) to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started. If the test results are inconclusive, de-escalation will be carried out.

Ethical considerations As both treatment strategies (i.e. aspirin plus clopidogrel or ticagrelor or prasugrel) are commonly used in treatment of ACS and considered standard care in Europe according to the ESC guidelines, no risks will be attached to treatment with any of the P2Y12 inhibitors. Patients who receive an individualized treatment strategy will possibly benefit from this, due to lower risk of bleeding complications.

연구 유형

중재적

등록 (추정된)

3120

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Eline Ploumen, MD, PhD
  • 전화번호: +31(0)53 487 2105
  • 이메일: e.ploumen@mst.nl

연구 장소

    • Overijssel
      • Almelo, Overijssel, 네덜란드, 7609 PP
        • Ziekenhuis Groep Twente
        • 연락하다:
          • Joost Kruik, MD
          • 전화번호: +31(0)88 708 33 00
          • 이메일: j.kruik@zgt.nl
      • Enschede, Overijssel, 네덜란드, 7512 KZ
        • Medisch Spectrum Twente
        • 연락하다:
          • Eline Ploumen, MD, PhD
          • 전화번호: +31(0)53 487 2105
          • 이메일: e.ploumen@mst.nl

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients of 18 years and older, who are capable of providing informed consent and were diag-nosed with an acute coronary syndrome

  • Patients with a coronary angiography showing obstructive coronary artery disease at time of di-agnosis (or up to 30 days thereafter)

  • Patients in whom no coronary angiography is performed during the index hospitalization or the first 30 days after the ACS, need to have at least one of the following:

    • known history of coronary artery disease (i.e., a previous MI, PCI, or coronary artery bypass grafting (CABG)),
    • proven myocardial defect by cardiac imaging that matches with previous MI,
    • proven myocardial ischemia, or
    • known coronary artery atherosclerosis as previously visualized.

Exclusion Criteria:

  • Known intolerance to or absolute contraindication for clopidogrel, ticagrelor, prasugrel or acetyl-salicylic acid.
  • Use of oral anticoagulant therapy.
  • Contra-indication for standard treatment with ticagrelor.
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or lap-aroscopic) within the past 6 months prior to randomization or any major surgical procedure planned 6 months after randomization.
  • Participation in another randomized cardiovascular device trial or randomized pharmacological trial related to antithrombotic and/or anticoagulant therapy before reaching the primary end-point.
  • Known pregnancy, adherence to scheduled follow-up is unlikely, or life expectancy is assumed to be less than 18 months.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Standard therapy

Dual antiplatelet therapy described at the cardiologist's discretion

Patients randomized for the standard therapy arm will receive dual antiplatelet therapy at the descretion of the cardiologist

실험적: Genotype based therapy

Dual antiplatelet therapy based on CYP2C19 genotype. In case of normal or ultrafast metabolizer, patient will receive Clopidogrel 30-days after acute coronary syndrome. In case of proven carrier of the loss-of-function allele, patient will continue with ticagrelor.

All patients with ACS can be enrolled. Randomization will take place at time of ACS diagnosis. For the first 30 days after the index event, patients will be treated with DAPT as prescribed by the cardiologist. Patients who experience a major event (any death, spontaneous MI, definite stent thrombosis, any stroke, and major bleeding) during the first 30 days will be excluded from the main analysis. For these patients, DAPT treatment will remain unchanged.

Included patients will be randomly assigned (1:1) to:

  1. Standard treatment at the discretion of the cardiologist
  2. Genotype-guided treatment In the patients randomized to the intervention arm genotyping will be performed and patients who do not carry a LOF allele will be classified as normal or ultrafast metabolizers. In these patients, de-escalation of P2Y12 inhibitor from standard therapy to clopidogrel will be performed around 30 days. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Ischemic endpoint
기간: At 18 months follow-up

Composition of cardiovascular death, myocardial infarction, definite stent thrombosis and ischemic stroke

At 18 months follow-up
Net Adverse Cardiovascular Events
기간: At 18 months follow-up

Composition of cardiovascular death, major bleeding, myocardial infarction, definite or probable stent thrombosis, and any stroke

At 18 months follow-up

2차 결과 측정

결과 측정
측정값 설명
기간
Adverse events
기간: At 18 months follow-up

Death, Myocardial infarction, repeat revascularization, stroke, stent thrombosis, and bleeding

At 18 months follow-up
Patient reported chest pain
기간: At 12- and 18-months follow-up

Severity of chest pain by the Canadian Cardiovascular Society Angina Grade score classified into four classes (I to IV) based on the amount of exertion that triggers the symptoms. The higher the class, the lower the exercise tolerance.

At 12- and 18-months follow-up
Patient reported dyspnea score
기간: At 12- and 18-months follow-up

Prevalance and impact of dyspnea on patient's daily activities classified by the Medical Research Council Dyspnea Scale. There are 5 grades (0 to 4). The higher the grade, the greater the impact.

At 12- and 18-months follow-up
Cost effectiveness analysis between the two treatment groups
기간: At 18 months follow-up

Compare healthcare costs and health outcomes of the two treatment arms. Healthcare costs are determined by extracting healthcare utilization data from electronic health records and multiplying these resource-use frequencies by their corresponding standard unit costs in euros. Health outcomes will be evaluated by assessing patient-reported quality of life through the validated questionnaires EuroQol 5 Dimensions (EQ5D). Quality adjusted life years (QALYs) will be derived from the EQ5D outcomes. Costs per QALY will be compared per treatment arm to compare cost-effectiveness.

At 18 months follow-up
Patient reported quality of life
기간: At 30 days, 12- and 18-months follow-up

Measured by the validated questionnaire EuroQol 5 Dimensions (EQ5D). The EQ5D evaluates a patient's health accross five core dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) giving it a score of 1 (no problems) to 5 (extreme problems).

At 30 days, 12- and 18-months follow-up

기타 결과 측정

결과 측정
측정값 설명
기간
Intention to treat analysis without 30-day adverse event exclusion
기간: At 12- and 18-months follow-up

The primary and secondary endpoints will be evaluated in all patients who were initially included at time of ACS diagnosis based on their randomized treatment, i.e., independent of adverse events in the first 30 days after ACS diagnosis and irrespective of received treatment.

At 12- and 18-months follow-up
Outcome differences in bleeding events
기간: At 18-months follow-up

To compare bleeding events (%) in both treatment arms.

At 18-months follow-up
Relation between patients ethnic background (self-reported) and clinical presentation
기간: At 18-months follow-up

Does self-defined ethnic background impact the incidence of clinical presentation (STEMI/NSTEMI/unstable angina). For example, is there an association between non-Western European ethnic background and the type of clinical presentation (STEMI/NSTEMI/unstable angina).

At 18-months follow-up
Relation between patients highest obtained education level and clinical outcome
기간: At 18-months follow-up

Is there a negative correlation between the highest obtained educational level and the incidence of the primary and secondary endpoints (%)

At 18-months follow-up
Correlation between Non-enrollers and enrollers
기간: 18 months

Clinical outcome (based on primary and secondary endpoints) of patients who were not enrolled vs patients who were enrolled in the study based on data from medical records

18 months
Outcome differences diabetes mellitus
기간: At 18 months follow-up

Differences in primary and secondary endpoints (%) of diabetic vs non-diabetic participants.

At 18 months follow-up
Outcome differences gender
기간: At 18 months follow-up

Differences in primary and secondary endpoints (%) of male vs female participants.

At 18 months follow-up
Outcome differences elderly
기간: At 18 months follow-up

Differences in primary and secondary endpoints (%) of elderly (>= 75 years) vs non-elderly participants.

At 18 months follow-up
Outcome differences invasive acute coronary syndrome treatment
기간: At 18 months follow-up

Differences in primary and secondary endpoints (%) of participants treated with percutaneous coronary intervention vs non-invasively-treated.

At 18 months follow-up
Outcome differences multivessel disease
기간: At 18 months follow-up

Differences in primary and secondary endpoints (%) of participants treated with multivessel percutaneous intervention vs non treated with mutlivessel percutaneous intervention.

At 18 months follow-up
Outcome differences acute coronary syndrome type
기간: At 18 months follow-up

Differences in primary and secondary endpoints (%) of participants with acute myocardial infarction vs unstable angina.

At 18 months follow-up
Relation between patients ethnic background (self-reported) and dual antiplatelet use
기간: At 18 months

Does self-reported ethnic background impact the incidence of dual antiplatelet use (therapy adherence). For example, does non-Western European ethnic background have an association with higher therapy adherence? This will be measured by self-reported adherence and pharmacist's records of dual antiplatelet therapy pick up.

At 18 months
Relation between patients ethnic background (self-reported) and clinical outcome
기간: At 18 months

Does ethnic background impact the incidence of the clinical outcome (primary and secondary endpoints). For example, is there an association between non-Western European ethnic background and lower rates of the primary or secondary endpoints.

At 18 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Clemens von Birgelen, MD, Prof. Dr., Medisch Spectrum Twente
  • 연구 책임자: Eline Ploumen, MD, PhD, Medisch Spectrum Twente

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 15일

기본 완료 (추정된)

2029년 11월 15일

연구 완료 (추정된)

2030년 3월 1일

연구 등록 날짜

최초 제출

2026년 8월 26일

QC 기준을 충족하는 최초 제출

2026년 11월 9일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다